ReviewNature reviews. Cardiology2014
Drug-coated balloon therapy in coronary and peripheral artery disease.
Review in Nature reviews. Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04893291 (Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II), which is not on this map. Cited by 84 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II
Who cites it
84 citing papers in PubMed, 6 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- Drug-coated balloon versus bare-metal stent for the treatment of symptomatic vertebral artery origin stenosis: a systematic review and meta-analysis.BMC neurology · 2026Pooled it
- Comparison of Hybrid Strategy With Drug-Coated Balloons Versus Stent-Only Strategy for Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis.Cardiovascular therapeutics · 2026Pooled it
- Drug-Coated Balloons versus Drug-Eluting Stents for the Treatment of De Novo Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials.Reviews in cardiovascular medicine · 2024Pooled it
- Drug-coated balloons versus drug-eluting stents in patients with in-stent restenosis: An updated meta-analysis with trial sequential analysis.Journal of cardiothoracic surgery · 2024Pooled it
- Drug-Coated Balloon Versus Plain Balloon Angioplasty for Hemodialysis Dysfunction: A Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2021Pooled it
- Comparison of drug-eluting balloon versus drug-eluting stent for treatment of coronary artery disease: a meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2018Pooled it
- Final 2-Year Results of the REFORM Study: A Randomized Trial of Biolimus DCB Versus Paclitaxel DCB for In-Stent Restenosis.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Trial
- One-year results of drug-coated balloons for long and occlusive Femoropopliteal artery disease: a single-arm trial.BMC cardiovascular disorders · 2020Trial
- Minimally invasive bioelectronic implants.Nature materials · 2026Review
- Drug-Coated Balloon-Based Strategy for De Novo Coronary Artery Disease Across Complex and High-Risk Indicated Percutaneous Coronary Intervention Risk Categories: A Multicenter Registry Study.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Observational
- Revascularization with drug-coated balloons alone in complex coronary artery disease: a systematic review.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Drug-coated balloons (DCB) for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis.Cardiovascular diagnosis and therapy · 2026Article
- Bioabsorbable Endovascular Adhesive Tape (BEAT) for Improving Vascular Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Numerical Simulation and Optimization of Drug-Coated Balloon Inflation for Vascular Stenosis.Bioengineering (Basel, Switzerland) · 2026Article
- Drug-coated balloons in complex large-vessel coronary artery disease: a comprehensive review of current evidence and future perspectives.Frontiers in cardiovascular medicine · 2026Review
- Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.Current treatment options in cardiovascular medicine · 2025Article
- Towards the Integration of an Anti-Contractile Compound Within Drug-Coated Balloon Therapy.Cardiovascular engineering and technology · 2025Article
- Applications and challenges of paclitaxel- coated balloons beyond coronary atherosclerotic heart disease.World journal of clinical cases · 2025Review
- Enhanced atherosclerosis molecular imaging and therapy with collagen hybridizing peptide functionalized albumin nanoparticles.Journal of nanobiotechnology · 2025Article
- Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Treatment for Large Vessel Coronary Artery Disease.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonstent-based local drug delivery during percutaneous intervention offers potential for sustained antirestenotic efficacy without the limitations of permanent vascular implants. Preclinical studies have shown that effective local tissue concentrations of drugs can be achieved using drug-coated balloon (DCB) catheters. Matrix coatings consisting of a mixture of lipophilic paclitaxel and hydrophilic spacer (excipient) are most effective. Clinical applications most suited to DCB therapy are those for which stent implantation is not desirable or less effective, such as in-stent restenosis, bifurcation lesions, or peripheral artery stenoses. Randomized trials have shown superiority of DCBs over plain-balloon angioplasty for both bare-metal and drug-eluting coronary in-stent restenosis, and similar efficacy as repeat stenting with a drug-eluting stent (DES). Bycontrast, randomized trials of DCBs in de novo coronary stenosis have, to date, not shown similar efficacy to standard-of-care DES therapy. In peripheral artery disease, DCB therapy has proven superior to plain-balloon angioplasty for treatment of de novo femoropoliteal and below-the-knee disease, and shown promising results for in-stent restenosis. Overall, however, despite many years of clinical experience with DCBs, the number of large, high-quality, randomized clinical trials is low, and further data are urgently needed across the spectrum of clinical indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.